Up-regulation of P-glycoprotein reduces intracellular accumulation of beta amyloid: investigation of P-glycoprotein as a novel therapeutic target for Alzheimer's disease
Authors:
- 11 June 2011
- journal article
- research article
- Published by Oxford University Press (OUP) in Journal of Pharmacy and Pharmacology
- Vol. 63 (8) , 1111-1118
Abstract
Objectives Several studies have suggested the efflux transporter P‐glycoprotein (P‐gp) to play a role in the etiology of Alzheimer's disease through the clearance of amyloid beta (Aβ) from the brain. In this study, we aimed to investigate the possibility of P‐gp as a potential therapeutic target for Alzheimer's disease by examining the impact of P‐gp up‐regulation on the clearance of Aβ, a neuropathological hallmark of Alzheimer's disease. Methods Uptake studies for 125I‐radiolabelled Aβ1–40, and fluorescent immunostaining technique for P‐gp and fluorescent imaging of Aβ1–40 were carried out in LS‐180 cells following treatment with drugs known to induce P‐gp expression. Key findings Approximately 10–35% decrease in 125I‐Aβ1–40 intracellular accumulation was observed in cells treated with rifampicin, dexamethasone, caffeine, verapamil, hyperforin, β‐estradiol and pentylenetetrazole compared with control. Also, fluorescent micrographs showed an inverse relationship between levels of P‐gp expression and 5‐carboxyfluorescein labelled Aβ (FAM‐Aβ1–40) intracellular accumulation. Quantitative analysis of the micrographs revealed that the results were consistent with those of the uptake studies using 125I‐Aβ1–40. Conclusions The investigated drugs were able to improve the efflux of Aβ1–40 from the cells via P‐gp up‐regulation compared with control. Our results elucidate the importance of targeting Aβ clearance via P‐gp up‐regulation, which will be effective in slowing or halting the progression of Alzheimer's disease.Keywords
This publication has 36 references indexed in Scilit:
- Calcium Ions Promote Formation of Amyloid β-Peptide (1–40) Oligomers Causally Implicated in Neuronal Toxicity of Alzheimer's DiseasePLOS ONE, 2011
- In Vivo Responses of the Human and Murine Pregnane X Receptor to Dexamethasone in MiceDrug Metabolism and Disposition, 2010
- Protective actions of sex steroid hormones in Alzheimer’s diseaseFrontiers in Neuroendocrinology, 2009
- Preparation of fluorescently‐labeled amyloid‐beta peptide assemblies: the effect of fluorophore conjugation on structure and functionJournal of Molecular Recognition, 2009
- Pregnane X Receptor (PXR) Regulates P-Glycoprotein at the Blood-Brain Barrier: Functional Similarities between Pig and Human PXRThe Journal of Pharmacology and Experimental Therapeutics, 2009
- The pregnane X receptor: from bench to bedsideExpert Opinion on Drug Metabolism & Toxicology, 2008
- Modulation of P-Glycoprotein at the Blood-Brain Barrier: Opportunities to Improve Central Nervous System PharmacotherapyPharmacological Reviews, 2008
- Rifampin and digoxin induction of MDR1 expression and function in human intestinal (T84) epithelial cellsBritish Journal of Pharmacology, 2008
- Increased P-glycoprotein expression and decreased phenobarbital distribution in the brain of pentylenetetrazole-kindled ratsNeuropharmacology, 2007
- Cerebral uptake of mefloquine enantiomers with and without the P‐gp inhibitor elacridar (GF1210918) in miceBritish Journal of Pharmacology, 2004